Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

This study is testing an alternative starting dose of niraparib — a maintenance drug used after chemotherapy for ovarian, fallopian tube, or peritoneal cancer — to see if a lower initial dose reduces the number of treatment interruptions and side effects while still maintaining effectiveness. **You may be eligible if...** - You are a woman aged 18 or older with a new diagnosis of stage III or IV high-grade ovarian, fallopian tube, or primary peritoneal cancer - You have completed at least 4 cycles of platinum-based chemotherapy with a good response - Your CA-125 tumor marker is in normal range or has dropped by 90% and stabilized - Your blood counts and organ function meet required levels **You may NOT be eligible if...** - You have previously received a PARP inhibitor (such as olaparib, rucaparib, or niraparib) - You are pregnant or planning to become pregnant during the study - You have a known BRCA1 or BRCA2 gene mutation (as standard olaparib is typically offered) - You have prior hematologic toxicity grade 3 or higher, or a history of myelodysplastic syndrome - You have significant heart disease or active liver/kidney conditions Talk to your doctor to see if this trial is right for you.